INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced it will present data on its INTASYL technology platform at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting in Montreal from October 6th-9th. The presentation, titled 'INTASYL Self-Delivering RNAi: a Flexible Platform for Cancer Treatment', will focus on how INTASYL can enhance ex vivo expansion processes to improve functionality and outcomes of adoptive cell therapies like NK, TIL, or CAR-T.
INTASYL's advantage lies in its simplified chemical composition, designed to reduce toxicity and improve tolerability and efficacy in therapeutic development. The poster presentation (Number P180) will be given by Melissa Maxwell on October 8th from 3:45-6:45 PM at the Centre Mont-Royal in Montreal.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ha annunciato che presenterà dati sulla sua piattaforma tecnologica INTASYL al 20° Meeting Annuale della Oligonucleotide Therapeutics Society (OTS) a Montreal dal 6 al 9 ottobre. La presentazione, intitolata 'INTASYL RNAi Auto-Somministrante: una Piattaforma Flessibile per il Trattamento del Cancro', si concentrerà su come INTASYL possa migliorare i processi di espansione ex vivo per migliorare la funzionalità e i risultati delle terapie cellulari adottive come NK, TIL o CAR-T.
Il vantaggio di INTASYL risiede nella sua composizione chimica semplificata, progettata per ridurre la tossicità e migliorare la tolleranza e l'efficacia nello sviluppo terapeutico. La presentazione del poster (Numero P180) sarà tenuta da Melissa Maxwell l'8 ottobre dalle 15:45 alle 18:45 al Centre Mont-Royal di Montreal.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) anunció que presentará datos sobre su plataforma tecnológica INTASYL en la 20ª Reunión Anual de la Sociedad de Terapias de Oligonucleótidos (OTS) en Montreal del 6 al 9 de octubre. La presentación, titulada 'INTASYL RNAi de Auto-Entrega: una Plataforma Flexible para el Tratamiento del Cáncer', se centrará en cómo INTASYL puede mejorar los procesos de expansión ex vivo para optimizar la funcionalidad y los resultados de las terapias celulares adoptivas como NK, TIL o CAR-T.
La ventaja de INTASYL radica en su composición química simplificada, diseñada para reducir la toxicidad y mejorar la tolerancia y eficacia en el desarrollo terapéutico. La presentación del póster (Número P180) será realizada por Melissa Maxwell el 8 de octubre de 3:45 a 6:45 PM en el Centre Mont-Royal de Montreal.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO)는 10월 6일부터 9일까지 몬트리올에서 열리는 제20회 올리고뉴클레오타이드 치료 학회(OTS)에서 INTASYL 기술 플랫폼에 대한 데이터를 발표할 것이라고 발표했습니다. 발표 제목은 'INTASYL 자기 전달 RNAi: 암 치료를 위한 유연한 플랫폼'으로, INTASYL이 NK, TIL 또는 CAR-T와 같은 수용세포 치료의 기능성과 결과를 개선하기 위해 ex vivo 확장 프로세스를 어떻게 향상시킬 수 있는지에 대해 집중할 것입니다.
INTASYL의 장점은 독성을 줄이고 치료 개발에서 내약성 및 효능을 개선하도록 설계된 간단한 화학 조성에 있습니다. 포스터 발표(번호 P180)는 10월 8일 오후 3:45부터 6:45까지 몬트리올의 Centre Mont-Royal에서 Melissa Maxwell에 의해 진행될 것입니다.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a annoncé qu'elle présentera des données sur sa plateforme technologique INTASYL lors de la 20e réunion annuelle de la Société des thérapies par oligonucléotides (OTS) à Montréal du 6 au 9 octobre. La présentation, intitulée 'INTASYL RNAi Auto-Administré : une Plateforme Flexible pour le Traitement du Cancer', se concentrera sur la manière dont INTASYL peut améliorer les processus d'expansion ex vivo pour augmenter la fonctionnalité et les résultats des thérapies cellulaires adoptives comme NK, TIL ou CAR-T.
L'avantage d'INTASYL réside dans sa composition chimique simplifiée, conçue pour réduire la toxicité et améliorer la tolérance et l'efficacité dans le développement thérapeutique. La présentation d'affiche (Numéro P180) sera donnée par Melissa Maxwell le 8 octobre de 15h45 à 18h45 au Centre Mont-Royal à Montréal.
Die Phio Pharmaceuticals Corp. (NASDAQ: PHIO) hat angekündigt, dass sie Daten zu ihrer INTASYL Technologieplattform auf dem 20. Jahresmeeting der Oligonucleotide Therapeutics Society (OTS) in Montreal vom 6. bis 9. Oktober präsentieren wird. Die Präsentation mit dem Titel 'INTASYL Selbstabgebendes RNAi: eine Flexible Plattform zur Krebsbehandlung' wird sich darauf konzentrieren, wie INTASYL ex vivo Expansionsprozesse verbessern kann, um die Funktionalität und Ergebnisse von adoptiven Zelltherapien wie NK, TIL oder CAR-T zu steigern.
Der Vorteil von INTASYL liegt in seiner vereinfachten chemischen Zusammensetzung, die darauf ausgelegt ist, die Toxizität zu reduzieren und die Verträglichkeit sowie die Wirksamkeit in der therapeutischen Entwicklung zu verbessern. Die Posterpräsentation (Nummer P180) wird am 8. Oktober von 15:45 bis 18:45 Uhr im Centre Mont-Royal in Montreal von Melissa Maxwell gehalten.
- Presentation at a major industry conference (OTS Meeting) showcasing INTASYL technology
- INTASYL's potential to enhance adoptive cell therapies
- INTASYL's simplified chemical composition may reduce toxicity and improve efficacy
- None.
--Data will be presented at the conference in October in Montreal
Marlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about INTASYL, its patented technology platform at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting. The conference will be held from October 6th-9th in Montreal, bringing together leading experts in oligonucleotide research.
Phio's presentation will focus on how INTASYL can enhance the ex vivo expansion process to improve the functionality and outcomes of adoptive cell therapies such as NK, TIL, or CAR-T. An advantage of the INTASYL technology is its simplified chemical composition, designed to reduce toxicity and improve both tolerability and efficacy, which are concerns in therapeutic development.
Presentation Details are as follows:
| Title: | INTASYL® Self-Delivering RNAi: a Flexible Platform for Cancer Treatment |
| Poster Number: | P180 |
| Poster Session: | II |
| Presenting Author: | Melissa Maxwell |
| Date and Time: | October 8 at 3:45-6:45 PM |
| Location: | Centre Mont-Royal, 2000 Mansfield St, Montreal, Quebec |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company focused on silencing specific genes using its proprietary INTASYL siRNA technology. In non-systemic applications, INTASYL can target and silence virtually any gene with high specificity across a wide range of tissue types. INTASYL is primarily designed to enhance the ability of immune cells to kill tumor cells and can play a key role in improving adoptive cell therapy. Notably, INTASYL is the only self-delivering RNAi technology, in that does not require specialized formulations or drug delivery systems.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/224321
FAQ
What is Phio Pharmaceuticals presenting at the 20th Annual OTS Meeting?
When and where is Phio Pharmaceuticals (PHIO) presenting at the OTS Meeting?
What are the potential advantages of Phio Pharmaceuticals' (PHIO) INTASYL technology?
